Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas-a meta-analysis.

Publisher: Oxford University Press Country of Publication: England NLM ID: 101721827 Publication Model: Print Cited Medium: Internet ISSN: 2515-5091 (Electronic) Linking ISSN: 25155091 NLM ISO Abbreviation: JNCI Cancer Spectr Subsets: MEDLINE

Original Publication: Oxford : Oxford University Press, [2017]-

Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Carboplatin*/therapeutic use ; Carboplatin*/administration & dosage ; DNA Mismatch Repair* ; Endometrial Neoplasms*/drug therapy ; Endometrial Neoplasms*/genetics ; Endometrial Neoplasms*/mortality; Female ; Humans ; Kaplan-Meier Estimate ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/epidemiology ; Neoplasm Recurrence, Local/genetics ; Progression-Free Survival ; Randomized Controlled Trials as Topic

Background: Chemo-immunotherapy is standard of care for women with recurrent or advanced mismatch repair deficient endometrial carcinoma. However, it is uncertain whether patients with mismatch repair deficient advanced or recurrent endometrial carcinoma derive less benefit from chemotherapy than those with mismatch repair proficient endometrial carcinoma.
Methods: We performed a meta-analysis of randomized controlled trials (RCTs) in advanced or recurrent endometrial carcinoma to determine the difference in the benefit of chemotherapy in mismatch repair deficient vs mismatch repair proficient endometrial carcinoma. Data on chemotherapy outcomes including objective response rate, progression-free survival (PFS), and overall survival were retrieved. We pooled these data using the inverse variance method and examined subgroup difference by mismatch repair status. We also compared differences in PFS and overall survival outcomes by creating individual patient data from the Kaplan-Meier curves of trial publications for sensitivity analyses.
Results: A total of 5 RCTs with 1137 participants (mismatch repair deficient, 26%; mismatch repair proficient, 74%) were included. All participants were treated with carboplatin-based chemotherapy. There was no difference between the mismatch repair deficient and mismatch repair proficient subgroups for objective response rate (66.5% vs 64.0%; P = .20 for subgroup difference), PFS (hazard ratio [HR] = 0.93, 95% confidence interval [CI] = 0.77 to 1.12; P = .44; median PFS = 7.6 vs 9.5 months) or overall survival (HR = 1.03, 95% CI = 0.73 to 1.44; P = .88; median overall survival = not reached vs 28.6 months).
Conclusions: Objective response rate, PFS, and overall survival were similar among those with mismatch repair deficient vs mismatch repair proficient endometrial cancer treated with front-line, platinum-doublet chemotherapy in RCTs. These findings reinforce the importance of combining chemotherapy together with immune checkpoint inhibitors until the results of trials comparing immune checkpoint therapy alone with combination therapy are available.
(© The Author(s) 2024. Published by Oxford University Press.)

Gynecol Oncol. 2023 Feb;169:78-84. (PMID: 36521352)
J Clin Oncol. 2010 Jul 10;28(20):3219-26. (PMID: 20498393)
J Clin Oncol. 2024 Jan 20;42(3):283-299. (PMID: 37864337)
Cancers (Basel). 2023 Jul 15;15(14):. (PMID: 37509300)
Clin Cancer Res. 2018 Dec 1;24(23):5939-5947. (PMID: 30068706)
J Clin Oncol. 2020 Oct 10;38(29):3388-3397. (PMID: 32749941)
Gynecol Oncol. 2023 Mar;170:282-289. (PMID: 36753816)
BMC Med Res Methodol. 2012 Feb 01;12:9. (PMID: 22297116)
Ann Transl Med. 2022 Apr;10(8):491. (PMID: 35571401)
N Engl J Med. 2023 Jun 8;388(23):2159-2170. (PMID: 36972022)
N Engl J Med. 2023 Jun 8;388(23):2145-2158. (PMID: 36972026)
Lancet Oncol. 2023 Mar;24(3):286-296. (PMID: 37052965)
Ann Oncol. 2017 May 1;28(5):1023-1031. (PMID: 28453697)
Ann Oncol. 2007 Mar;18(3):409-20. (PMID: 17150999)

BG3F62OND5 (Carboplatin)

Date Created: 20241021 Date Completed: 20241111 Latest Revision: 20241121

20241122

PMC11552623

10.1093/jncics/pkae101

39432670